A small molecule inhibitor of EZH2 drove intratumoral Tregs to acquire pro-inflammatory functions, leading to remodeling the tumor microenvironment and enhancing the anticancer immunity without provoking systemic autoimmunity (66). This evidence concerns the gene EZH2 and neoplasm.